LIGHT protein suppresses tumor growth by augmentation of immune response

Immunology Letters

Volumn 127, Issue 1, 2009, Pages 33-38

  Morishige, Tomohiro ^a   Yoshioka, Yasuo ^a   Inakura, Hiroshi ^a   Tanabe, Aya ^a   Watanabe, Hikaru ^a   Yao, Xinglei ^a   Tsunoda, Shin ichi ^b   Tsutsumi, Yasuo ^a,b   Mukai, Yohei ^a   Okada, Naoki ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Cancer immunotherapy; Cytokine; Protein therapy; Recombinant protein; Tumor necrosis factor

Indexed keywords

GAMMA INTERFERON; LIGHT PROTEIN; PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL INCLUSION; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPH NODE; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RECEPTOR AFFINITY; SPLEEN;

ANIMALS; ANTIGENS, NEOPLASM; CELL GROWTH PROCESSES; CLONING, MOLECULAR; ESCHERICHIA COLI; HT29 CELLS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPH NODES; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECOMBINANT PROTEINS; SPLEEN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 70350704674     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2009.08.010     Document Type: Article

References (36)

1. Yoshioka Y., Tsutsumi Y., Nakagawa S., and Mayumi T. Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach. Curr Vasc Pharmacol 2 (2004) 259-270
2. Gattinoni L., Powell Jr. D.J., Rosenberg S.A., and Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6 (2006) 383-393
3. Paulos C.M., Kaiser A., Wrzesinski C., Hinrichs C.S., Cassard L., Boni A., et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13 (2007) 5280-5289
4. Mukai Y., Yoshioka Y., and Tsutsumi Y. Phage display and PEGylation of therapeutic proteins. Comb Chem High Throughput Screen 8 (2005) 145-152
5. Dunn G.P., Koebel C.M., and Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6 (2006) 836-848
6. Yu P., and Fu Y.X. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev 19 (2008) 285-294
7. Wang Y., Zhu M., Miller M., and Fu Y.X. Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunol Rev 229 (2009) 232-243
8. Bremer E., de Bruyn M., Wajant H., and Helfrich W. Targeted cancer immunotherapy using ligands of the tumor necrosis factor super-family. Curr Drug Targets 10 (2009) 94-103
9. Yang J.C., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
10. Motzer R.J., Rakhit A., Schwartz L.H., Olencki T., Malone T.M., Sandstrom K., et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4 (1998) 1183-1191
11. Schiller J.H., Pugh M., Kirkwood J.M., Karp D., Larson M., and Borden E. Eastern Cooperative Group Trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res 2 (1996) 29-36
12. Yu P., Rowley D.A., Fu Y.X., and Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 18 (2006) 226-231
13. Singh S., Ross S.R., Acena M., Rowley D.A., and Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 175 (1992) 139-146
14. Ochsenbein A.F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96 (1999) 2233-2238
15. Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., Yu G.L., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 8 (1998) 21-30
16. Harrop J.A., McDonnell P.C., Brigham-Burke M., Lyn S.D., Minton J., Tan K.B., et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 273 (1998) 27548-27556
17. Murphy M., Walter B.N., Pike-Nobile L., Fanger N.A., Guyre P.M., Browning J.L., et al. Expression of the lymphotoxin β receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ 5 (1998) 497-505
18. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5 (2004) 141-149
19. Stopfer P., Mannel D.N., and Hehlgans T. Lymphotoxin-β receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J Immunol 172 (2004) 7459-7465
20. Tamada K., Shimozaki K., Chapoval A.I., Zhai Y., Su J., Chen S.F., et al. LIGHT, a TNF-Like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 164 (2000) 4105-4110
21. Rooney I.A., Butrovich K.D., Glass A.A., Borboroglu S., Benedict C.A., Whitbeck J.C., et al. The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 275 (2000) 14307-14315
22. Yamamoto Y., Tsutsumi Y., Yoshioka Y., Nishibata T., Kobayashi K., Okamoto T., et al. Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity. Nat Biotechnol 21 (2003) 546-552
23. Shibata H., Kamada H., Kobayashi-Nishibata K., Yoshioka Y., Nishibata T., Abe Y., et al. Role of amino acid residue 90 in bioactivity and receptor binding capacity of tumor necrosis factor mutants. Biochim Biophys Acta 1774 (2007) 1029-1035
24. Yao X., Yoshioka Y., Eto Y., Morishige T., Okada Y., Mizuguchi H., et al. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Biochem Biophys Res Commun 362 (2007) 419-424
25. Reiter Y., and Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol 16 (1998) 513-520
26. Schmidt F.R. Recombinant expression systems in the pharmaceutical industry. Appl Microbiol Biotechnol 65 (2004) 363-372
27. Yu P., Lee Y., Wang Y., Liu X., Auh S., Gajewski T.F., et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 179 (2007) 1960-1968
28. Zhang J., Wang Q., Zhao D., and Cao X. Induction of potent anti-tumor immunity by direct injection of Ad-LIGHT at the site of tumor inoculation. Cytotherapy 9 (2007) 386-396
29. Loeffler M., Le'Negrate G., Krajewska M., and Reed J.C. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA 104 (2007) 12879-12883
30. Eto Y., Yoshioka Y., Mukai Y., Okada N., and Nakagawa S. Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm 354 (2008) 3-8
31. Yoshioka Y., Tsutsumi Y., Ikemizu S., Yamamoto Y., Shibata H., Nishibata T., et al. Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency. Biochem Biophys Res Commun 315 (2004) 808-814
32. Shibata H., Yoshioka Y., Ikemizu S., Kobayashi K., Yamamoto Y., Mukai Y., et al. Functionalization of tumor necrosis factor-α using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 10 (2004) 8293-8300
33. Shibata H., Yoshioka Y., Ohkawa A., Minowa K., Mukai Y., Abe Y., et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-α antagonist. J Biol Chem 283 (2008) 998-1007
34. Anand S., Wang P., Yoshimura K., Choi I.H., Hilliard A., Chen Y.H., et al. Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. J Clin Invest 116 (2006) 1045-1051
35. Wang J., Anders R.A., Wang Y., Turner J.R., Abraham C., Pfeffer K., et al. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J Immunol 174 (2005) 8173-8182
36. Lukashev M., LePage D., Wilson C., Bailly V., Garber E., Lukashin A., et al. Targeting the lymphotoxin-β receptor with agonist antibodies as a potential cancer therapy. Cancer Res 66 (2006) 9617-9624